Impax Laboratories (IPXL)
Impax Laboratories Profit Margin: 9.62%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
IPXL Profit Margin Rankings
| Overall | 68th percentile | 1377 of 4397 |
| Sector | 77th percentile | 107 of 469 in Healthcare |
| Industry | 30th percentile | 14 of 20 in Drug Manufacturers - Major |
IPXL Profit Margin Range, Past 5 Years
| Minimum | -28.63% | Sep 2008 |
| Maximum | 40.67% | Mar 2010 |
| Average | 12.58% |
About Profit Margin
Profit margin represents the percentage of revenue that a company keeps as profit after accounting for fixed and variable costs. It is calculated by dividing net income by revenue. The profit margin is mainly used for internal comparisons, because acceptable profit margins vary between industries. In general, narrow profit margins indicate increased volatility. For companies with significant fixed costs, wide profit margins reduce the risk that a decline in sales will cause a net profit loss.
Displayed as a percentage, profit margin can be thought as the amount of profit that a company keeps per dollar of revenue. For example, if a company has a profit margin of 43%, the company keeps $.43 of each dollar of revenue.
Learn More
You may also be interested in these IPXL related companies
IPXL News
Top 4 Small-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest Profit Margin
May 23, 2:27AM Benzinga
May 23, 2:27AM Benzinga
Impax Laboratories Announces Voting Results from 2012 Annual Meeting of Stockholders
May 22, 4:05PM Business Wire
May 22, 4:05PM Business Wire
Auriga Reiterates a 'Buy' on Impax Laboratories (IPXL); Positive After Meetin with Management
May 14, 10:17AM Street Insider
May 14, 10:17AM Street Insider
Impax Laboratories to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
May 10, 9:00AM Business Wire
May 10, 9:00AM Business Wire
$IPXL forms bearish "Double Top" chart pattern. http://stks.co/3l1f
about 21 days ago by RecogniaEvents
about 21 days ago by RecogniaEvents
Needham & Company Maintains a 'Hold' on Impax Laboratories (IPXL); Clearing Q1 Hurdle; Regulatory Clouds Remain
May 02, 9:02AM Street Insider
May 02, 9:02AM Street Insider
$IPXL Impax Labs falls on weak sales, new FDA warning
http://stks.co/3bjj $$
about 29 days ago by stockspot
about 29 days ago by stockspot
News related to $IPXL, currently -1.8% since open: 'Endo Pharma turns 1Q loss on $100M pre-tax charge' http://stks.co/3bg7
about 29 days ago by TradeBot
about 29 days ago by TradeBot
Listen to $IPXL Q1 2012 earnings call - live at 11:00 AM, ondemand after - http://stks.co/3bTc
about 29 days ago by earningscast
about 29 days ago by earningscast
Impax Laboratories Reports Adjusted First Quarter 2012 EPS of $0.52; GAAP EPS of $0.18
May 01, 7:00AM Business Wire
May 01, 7:00AM Business Wire
Auriga Maintains a 'Buy' on Impax Laboratories (IPXL); Generic Adderall XR Sales In-Line
Apr 26, 10:45AM Street Insider
Apr 26, 10:45AM Street Insider
Impax Laboratories Confirms Patent Challenge Relating to Generic GRALISEĀ® 300 mg and 600 mg
Apr 12, 9:20AM Benzinga
Apr 12, 9:20AM Benzinga
Impax Laboratories Schedules Conference Call and Webcast for First Quarter 2012 Financial Results
Apr 04, 8:00AM Business Wire
Apr 04, 8:00AM Business Wire
Big weekend Market Newsletter http://stks.co/3B8T also includes watch list stocks $ALR, $BOE, $EGHT, $GGP, $IPXL, $TRLG
about 58 days ago by StockTiger
about 58 days ago by StockTiger
Comprehensive Market Newsletter 60+ charts http://stks.co/3AaV plus additions to watch list $ALR, $BOE, $EGHT, $GGP, $IPXL, $TRLG
about 59 days ago by StockTiger
about 59 days ago by StockTiger
Impax Laboratories Enters Into Development, Supply and Distribution Agreement with TOLMAR
Mar 26, 8:03AM Benzinga
Mar 26, 8:03AM Benzinga
Impax Laboratories Enters Into Development, Supply and Distribution Agreement with TOLMAR, Inc.
Mar 26, 8:00AM Business Wire
Mar 26, 8:00AM Business Wire
$IPXL http://stks.co/2uy4 Consolidating wedge, over 23.80 has MM to 28
about 74 days ago by harmongreg
about 74 days ago by harmongreg
Canaccord Genuity Reiterates a 'Buy' on Impax Laboratories (IPXL); Our Top Small Cap Pick is Catalyst Heavy
Mar 14, 8:59AM Street Insider
Mar 14, 8:59AM Street Insider
RT @BlueFielder $IPXL set to run like hell < nice Hammer today, thanks for that.
about 86 days ago by 1nvestor
about 86 days ago by 1nvestor
Canaccord Genuity Maintains a 'Buy' on Impax Laboratories (IPXL); Thesis Unchanged After Meetings With Management
Mar 05, 10:11AM Street Insider
Mar 05, 10:11AM Street Insider
Top 4 Small-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest Revenue
Mar 02, 2:59AM Benzinga
Mar 02, 2:59AM Benzinga
Listen to $IPXL Q4 2011 earnings call - live at 11:00 AM, ondemand after - http://stks.co/2av6
about 92 days ago by earningscast
about 92 days ago by earningscast
Relatively strong, under the radar earnings reports from $IPXL $VSI $MENT this morning
about 92 days ago by ivanhoff
about 92 days ago by ivanhoff
Spinning Top to end the week, now a range to play. Let it show its hand on 2/27 first for a new pos. $IPXL http://chart.ly/tff9hrf
about 94 days ago by 1nvestor
about 94 days ago by 1nvestor
@cowboy1 $IPXL is scheduled to report earnings soon so I would be careful with that one.
about 97 days ago by TazTrader
about 97 days ago by TazTrader
$IPXL is 5.0 pct. up since open on unusual high volume and 0.1 pct. up since close.
about 111 days ago by TradeBot
about 111 days ago by TradeBot
$IPXL 200 Day SMA Cross - Price crossed below 200 day SMA (20.5349). Confirmed by volume.
about 111 days ago by TradeIdeasQuant
about 111 days ago by TradeIdeasQuant
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| IPXL | 21.15 | -0.28 | -1.31% | 1.432B |
| IPW | 22.78 | +0.00 | +0.00% | |
| IPU | 15.00 | -0.22 | -1.43% | |
| IPT | 0.2112 | +0.01 | +3.53% | 5.155M |
| IPSU | 6.34 | -0.01 | -0.16% | 77.60M |
| IPG | 10.71 | -0.28 | -2.55% | 4.903B |
| IPF | 14.84 | +0.00 | +0.00% | |
| IPCM | 35.12 | -0.32 | -0.90% | 585.47M |
| IPCI | 2.96 | +0.00 | +0.00% | 47.09M |
| IPCC | 54.06 | -0.55 | -1.01% | 644.40M |